Biological Therapy in Previously Treated Patients With Non-small Cell Lung Cancer

Status unconfirmed · Phase 2

Conditions studied: Lung Cancer

In brief

RATIONALE: Interleukin-2 may stimulate a person's white blood cells to kill non-small cell lung cancer cells. PURPOSE: Phase II trial to study the effect of biological therapy with interleukin-2 in patients with previously treated non-small cell lung cancer.

Key facts

Study ID

NCT00003090

Run by

Cancer Biotherapy Research Group

People needed

30

Starts

1996-01-01

Last updated by the study team

2013-11-06

Who can join

Age: any. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Bloomington Hospital — Bloomington, Indiana, United States
• Bergan Mercy Medical Center — Omaha, Nebraska, United States
• St. Joseph Regional Cancer Center — Bryan, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.